A solid-phase enzyme-linked assay for vitamin B12

Department of Chemistry University of Kentucky 40506 Lexington KY USA
Microchimica Acta (Impact Factor: 3.74). 12/1988; 97(1):65-73. DOI: 10.1007/BF01197285
Source: OAI


A new solid-phase enzyme-linked competitive binding assay for vitamin B12 (cyanocobalamin) is described. The assay is based on the competition between analyte B12 molecules and a glucose-6-phosphate dehydrogenase-vitamin B12 conjugate for a limited number of R-protein binding sites immobilized on sepharose particles. After appropriate incubation and washing steps, the enzyme activity bound to the solid-phase is inversely related to the concentration of B12 in the sample. Under optimized conditions, the method can detect B12 in the range of 310–10–110–8
M (using 100l sample) with high selectivity over other biological molecules.

2 Reads
  • Source
    • "The immobilized phase of the assay was prepared by coupling CN-Cbl to keyhole limpet hemocyanin (KLH) with the bromoacetyl bromide procedure , which improved the sensitivity compared with earlier work. A solid phase enzyme-linked competitive binding assay for CN- Cbl was described by Tsalta and coworkers in 1989 based on the competition between the analyte and glucose-6-phosphate dehydrogenase–vitamin B 12 conjugate for a limited number of R-protein binding sites immobilized on Sepharose particles [81]. Sample pretreatment with denaturing agents and neutralizing deactivating agents and a vitamin B 12 enzyme immunoassay was described by Watkins and coworkers in 1992 [82]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin B(12) is an organic compound containing cobalt and essential nutrient for all cell development and human growth. The daily requirements of vitamin B(12) are very low and deficiencies reported to be at picogram level, thus it necessitates detecting vitamin B(12) at high sensitivity in biological samples. It is also reported that several functional groups in the vitamin B(12) and analogs make more difficult to analyze in biological samples for routine analysis, as analogs are not useful for human metabolism. Many methods have been reported for its analysis like radioisotope, high performance liquid chromatography (HPLC), spectrophotometry, fluorimetric assay, capillary electrophoresis (CE) and atomic absorption spectrometry (AAS). These conventional analytical techniques found to be time consuming, tedious, less safe, low sensitivity and expensive, where as combination of immuno-chemiluminescence and biosensor based analysis found to be ultra sensitive having wide application for the detection of vitamin B(12). This review aims to present a concise survey of articles for all analytical practitioners for better understanding in trends of analysis in vitamin B(12). The format selected for this survey divides coverage into various aspects like introduction of complexity in vitamin B(12) structure with challenges in extraction and analysis by various analytical methods followed by problems in raising antibody against vitamin B(12.) Within the scope of each of these areas, key articles have been selected to describe current practices in analysis of vitamin B(12) with proposed novel approaches.
    Analytical Biochemistry 11/2009; 398(2):139-49. DOI:10.1016/j.ab.2009.06.041 · 2.22 Impact Factor

  • Pharmaceutical Chemistry Journal 10/1995; 29(10):722-731. DOI:10.1007/BF02219537 · 0.45 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The mode of neuronal death caused by cerebral ischemia and reperfusion appears on the continuum between the poles of catastrophic necrosis and apoptosis: ischemic neurons exhibit many biochemical hallmarks of apoptosis but remain cytologically necrotic. The position on this continuum may be modulated by the severity of the ischemic insult. The ischemia-induced neuronal death is an active process (energy dependent) and is the result of activation of cascades of detrimental biochemical events that include perturbion of calcium homeostasis leading to increased excitotoxicity, malfunction of endoplasmic reticulum and mitochondria, elevation of oxidative stress causing DNA damage, alteration in proapoptotic gene expression, and activation of the effector cysteine proteases (caspases) and endonucleases leading to the final degradation of the genome. In spite of strong evidence showing that brain infarction can be reduced by inhibiting any one of the above biochemical events, such as targeting excitotoxicity, up-regulation of an antiapoptotic gene, or inhibition of a down-stream effector caspase, it is becoming clear that targeting a single gene or factor is not sufficient for stroke therapeutics. An effective neuroprotective therapy is likely to be a cocktail aimed at all of the above detrimental events evoked by cerebral ischemia and the success of such therapeutic intervention relies upon the complete elucidation of pathways and mechanisms of the cerebral ischemia-induced active neuronal death.
    International Review of Cytology 02/2002; 221:93-148. DOI:10.1016/S0074-7696(02)21011-6 · 9.00 Impact Factor
Show more


2 Reads
Available from